CCM
LCTX icon

Consonance Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Consonance Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-668,620
Closed -$1.62M – 24
2015
Q3 		$1.62M Sell
668,620
-143,602
-18% -$372K 0.23% 23
2015
Q2 		$2.38M Sell
812,222
-1,173,357
-59% -$4.55M 0.24% 25
2015
Q1 		$7.96M Hold
1,985,579
– – 0.73% 24
2014
Q4 		$5.98M Buy
+1,985,579
New +$5.37M 0.77% 23

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Consonance Capital Management's LCTX Position: Q4 2015 in Review

Consonance Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2015, closing a stake of 668,620 shares — an estimated $1.62M sold.

Consonance Capital Management first reported a position in LCTX in Q4 2014 and held it in 4 quarters. The position peaked at $7.96M in Q1 2015. 68 funds tracked by Wall St. Rank hold LCTX as of Q4 2015.

  • Consonance Capital Management reported no remaining Lineage Cell Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Consonance Capital Management sold 668,620 Lineage Cell Therapeutics shares in Q4 2015, an estimated $1.62M.
  • Consonance Capital Management first reported a position in Lineage Cell Therapeutics in Q4 2014 and held it in 4 quarters.
  • Consonance Capital Management's Lineage Cell Therapeutics position peaked at $7.96M in Q1 2015.
  • 68 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2015.

Based on Consonance Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.